We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
BIVI

Price
10.30
Stock movement down
-0.40 (-2.56%)
Company name
Biovie Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
114.52M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-99.61%
3 year return
-91.53%
5 year return
-85.53%
10 year return
-
Last updated: 2025-09-12

DIVIDENDS

BIVI does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open15.60
Daily high15.65
Daily low14.60
Daily Volume26K
All-time high587500.00
1y analyst estimate60.00
Beta1.07
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
BIVIS&P500
Current price drop from All-time high-100.00%-1.46%
Highest price drop-100.00%-56.47%
Date of highest drop21 Aug 20259 Mar 2009
Avg drop from high-82.68%-10.99%
Avg time to new high441 days12 days
Max time to new high2161 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
BIVI (Biovie Inc) company logo
Marketcap
114.52M
Marketcap category
Small-cap
Description
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Employees
13
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...